As President Trump enters his second month in office, he does so with clear momentum delivering on a mandate from the American people. The American people overwhelmingly voted to return him to the White House, and with that, they endorsed his promises to prioritize government efficiency and reduce taxpayer spending. This sounds very promising, but while President Trump’s goals are ambitious and necessary, it must be recognized that Congress will play a pivotal role in enacting those policies, and they need to do so swiftly. 

One area that demands immediate attention is the affordability challenge for prescription drugs. Unfortunately, some of the PBM proposals currently under consideration in Congress miss the mark. Instead of reducing costs, these policies – likely considered in a Continuing Resolution or reconciliation package – would create unnecessary regulations that expand the role of the federal government into the private sector while doing little to address the root causes of high drug prices – a result of big pharma setting exorbitant prices. This would not just a policy misstep: it’s a blatant disregard for the mandate President Trump received from voters to limit government and cut spending.

Let me be........

© Townhall